FOOTHILL RANCH, Calif., Dec. 28 -- CardioGenesis Corp. has announced the closing of a $2.0 million private placement of its common stock with the State of Wisconsin Investment Board. The private placement involved 2,222,225 shares of CardioGenesis common stock at a fixed price and terms agreed in mid-December. CardioGenesis is a medical device company specializing in the treatment of cardiovascular disease and is the leader in products that stimulate cardiac angiogenesis. The company's Holmium:YAG laser system and disposable fiber optic accessories are used to perform an FDA-cleared surgical procedure known as transmyocardial revascularization to treat patients suffering from angina.